Acurx Pharmaceuticals Inc... (ACXP)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Company Description
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections.
Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections.
The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae.
Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
Country | United States |
IPO Date | Jun 25, 2021 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 4 |
CEO | David P. Luci CPA, Esq., J.D. |
Contact Details
Address: 259 Liberty Avenue Staten Island, New York United States | |
Website | https://www.acurxpharma.com |
Stock Details
Ticker Symbol | ACXP |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001736243 |
CUSIP Number | 00510M104 |
ISIN Number | US00510M1045 |
Employer ID | 00-0000000 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
David P. Luci CPA, Esq., J.D. | Co-Founder, President, Chief Executive Officer, Corporate Secretary & Director |
Robert G. Shawah CPA, CPA | Co-Founder & Chief Financial Officer |
Robert J. DeLuccia | Co-Founder & Executive Chairman |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Jan 17, 2025 | D | Filing |
Jan 08, 2025 | 4 | Filing |
Jan 08, 2025 | 4 | Filing |
Jan 08, 2025 | 4 | Filing |
Jan 08, 2025 | 4 | Filing |
Jan 08, 2025 | 4 | Filing |
Jan 08, 2025 | 4 | Filing |
Jan 07, 2025 | 424B5 | Filing |
Jan 07, 2025 | 8-K | Current Report |
Jan 06, 2025 | 424B3 | Filing |